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Summary 
Analysis of synthetic tri- and tetrapeptides has previously indicated that N-formylation is required 
for high biological activity when they react with the phagocyte N-formylpeptide receptor, suggesting 
that the natural ligand for the receptor is from bacterial and/or mitochondrial sources. To explore 
this requirement further, we synthesized the pentapeptide methionyl-norleucyl-leucyl-phenylalanyl- 
phenylalanine  (MNIeLFF)  and studied the effects of different NH2-terminal modifications  on 
its activity. N-formyl-MNleLFF induced transient alterations of [Ca2+]i and superoxide produc- 
tion in human neutrophils with 10- and 100-fold greater potency, respectively, than the proto- 
type N-formylpeptide,  N-formylmethionyl-leucyl-phenylalanine  (fMLF). Surprisingly, N-acetyl- 
MNleLFF was as potent as N-formyl-MNleLFF. Moreover, the unacylated counterpart H-MNleLFF 
was also highly active, having an ECs0 for calcium mobilization of 10 riM, and for respiratory 
burst activation of 100 nM. All three pentapeptides could completely desensitize calcium transients 
elicited by stimulation of neutrophils with fMLF, whereas the neutrophil chemoattractants CSa 
and interleukin 8 only weakly affected fMLF-induced transients,  suggesting that they activate 
neutrophils via the same receptor as fMLF. Finally, all three pentapeptides activated the recombinant 
human N-formylpeptide receptor expressed in frog oocytes, but did not effectively activate related 
phagocyte receptors. These data broaden the potential sources of natural ligands for the N-formyl- 
peptide receptor from N-formylated bacterial and mitochondrial products to other nonformylated 
endogenous peptides. 
I 
n studies designed to delineate the mechanisms by which 
bacterial infections induce pus formation, Schiffmann et 
al. (1) investigated the ability ofpeptides derived from super- 
natants  of bacterial  cultures  to  chemoattract mammalian 
phagocytes in vitro. The NHz termini of the peptides were 
blocked and could not be sequenced. Since the NH2-terminal 
residue of all bacterial proteins is N-formylmethionyl, a se- 
ries of N-formylmethionyl  peptides was synthesized and these 
were found to activate phagocyte functions with high potency. 
Specific, high affanity  receptors were demonstrated on phago- 
cytes, and N-formylation of the tested peptides was shown 
to be required for high activity (2-4). Acetylated and non- 
acylated tri- and tetrapeptides have been reported to have little 
if any ability to activate phagocytes. The synthetic N-formyl- 
peptide  N-formylmethionyl-leucyl-phenylalanine (fMLF) 1 
I Abbreviations used in this paper: ac, acetyl; f, formyl; fMLF, N-formyl- 
methionyl-leucyl-phenylalanine; FPR, human N-formylpeptide  receptor; 
H-MLF, methionyl-leucyl-phenylalanine; MNleLFF, methionyl-norleucyl- 
leucyl-phenylalanyl-phenvlalanine. 
became a prototype for the study of neutrophil activation 
by chemoattractants. 
The sequence of a high a~nity human N-formylpeptide 
receptor  (FPR) was deduced from cloned cDNAs in 1990 
(5). Two human genes (gene symbols FPRLI  and FPRL2) 
and their corresponding phagocyte cDNAs have been cloned 
that encode proteins with 69 and 56% amino acid sequence 
identity to FPR (6-9). The FPRL1 receptor  (FPILL1R) is 
a low affinity receptor for fMLF (Ka =  430 nM; ECs0 for 
calcium mobilization > 100 nM) (6, 10); the putative FPRL2 
product has no known ligand (9). When FPR is expressed 
in rat basophilic leukemia cells, it mediates degranulation and 
cytoskeletal remodeling, responses that mimic neutrophil re- 
sponses to fMLF (11). When FPR is expressed in adenovirus- 
transformed  human embryonic kidney 293 cells, the same 
peptide binding selectivity is observed as for native neutro- 
phil binding sites (12). Taken together, these findings strongly 
suggest that FPR is the receptor responsible for most if not 
all neutrophil responses to fMLF. 
Despite these advances, the source of natural ligands for 
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tial for ligand activity, the only known natural sources would 
be bacteria and mitochondria. In fact, Marasco et al. (13) have 
shown that the major chemotactic peptide for neutrophils 
produced by Escherichia  coil is N-formylated, and is identical 
in sequence to the synthetic prototype fMLF. Although Carp 
(14) has shown that mitochondrial proteins can attract neu- 
trophils in vitro, the requirement for N-formylation for ac- 
tivity and the receptor target have not been defined. 
To further examine the requirement of N-formylation for 
activation of FPR, we synthesized the pentapeptide methionyl- 
norleucyl-leucyl-phenylalanyl-phenylalanine  (MNleLFF) and 
studied the effects of different NH2-terminal modifications 
on its activity. We now report that the acetylated and non- 
acylated forms of the peptide could potently and specifically 
activate both natural and recombinant sources of FPR. Thus, 
natural ligands for FPR may not be restricted to bacterial 
and mitochondrial sources. 
Materials  and Methods 
Materials.  fMLF,  methionyl-leucyl-phenylalanine  (H-MLF), ATE 
recombinant human C5a, and superoxide dismutase were from 
Sigma Chemical Co. (St. Louis, MO). FURA-2 AM was from 
Molecular Probes, Inc. (Eugene, OR). Recombinant human 72 
amino acid IL-8 was obtained from PeproTech (Rocky Hill, NJ). 
Peptide Synthesis.  Peptides  were prepared by solid-phase pep- 
tide synthesis  using the 9-fluoroenylmethoxycarbonyl  (FMoc) group 
for protection of the amino group. Deprotection was with 25% 
piperidine. Formylation was carried out using carbodiimide/hy- 
droxybenztriazole  (ECD/HOIKI'). Acetylation  was carried  out using 
acetic anhydride. Removal from the resin was with trifluoroacetic 
acid. Peptides were purified using reverse-phase HPLC and were 
homogeneous. Lyophilized  peptides  were aliquoted  as 10 mM stocks 
in DMSO, stored at  -20~  and diluted into  aqueous buffers 
before use. 
Preparation of Neutrolshils.  Granulocytes  were isolated from 
heparinized human peripheral blood by Ficoll-Hypaque discon- 
tinuous density gradient centrifugation, dextran sedimentation,  and 
hypotonic lysis. Cells were always >95% neutrophils. All experi- 
ments were conducted within 6 h of cell isolation. 
Intracellular Calcium Measurements in Neutrophils.  Cells  (107/ml) 
were incubated in HBSS with Ca  2+ , Mg  z+ , and 10 mM Hepes, 
pH 7.4, containing 2.5/~M FURA-2 AM for 30 min at 37~  in the 
dark. The cells were subsequently washed twice with HBSS, and 
resuspended at 2 x  106 cells/ml. 2 ml of the cell suspension were 
placed in a continuously-stirred cuvette maintained at 37~  (Del- 
taScan; Photon Technology  International Inc., S. Brunswick, NJ). 
Fluorescence was monitored at ~xl  =  340 nm, ~x2  =  380 nm, 
and ~  =  510 nm, and the data presented as the relative ratio 
of fluorescence  at 340 and 380 nm for experiments with FURA-2. 
Data were collected every 200 ms. 
Receptor Reconstitution in Xenopus Oocytes.  cDNAs and genes 
for FPR, FPRL1, and FPRL2 have been previously cloned, and 
expression constructs described (6, 9, 15). Capped sense RNA was 
synthesized  by first linearizing  plasmid  constructs by digestion  with 
an appropriate restriction endonuclease  which cut the plasmid once 
in the 3' polylinker region, followed  by in vitro transcription with 
either T3 or T7 RNA polymerase  using a kit and instructions from 
the manufacturer (Stratagene, La  Jolla, CA). All cRNA transcripts 
were shown to migrate as single appropriately sized  bands by dena- 
turing agarose  gel electrophoresis. The materials  and methods used 
for the calcium efftux assay were as described (15) with minor 
modifications. 1-2 d after harvesting, defolliculated  oocytes were 
microinjected with 10 ng of the indicated receptor cRNA with 
or without 200 ng of HL-60 cell poly(A) + RNA.  The HL-60 
RNA supplies mRNA for an undefined complementary human 
factor that along with FPR and the FPRL1 receptor is necessary 
to establish a calcium-mobilizing signal transduction pathway for 
fMLF in the oocyte (10, 15). Microinjection of either the cRNA 
or HL-60 RNA separately  failed to confer fMLF sensitivity to the 
oocyte. Oocytes  were then incubated  at 20-23~  for 3-5 d in ND96 
media (96 mM NaC1, 1 mM KC1, 1 mM MgC12, 1.8 mM CaClz, 
pH 7.45). Oocytes were then incubated with 4SCaZ  + (100/zCi/ml) 
for 4 h. After 10 washes with ND96, individual  oocytes  were stimu- 
lated with ligands. Data are presented as the mean +  SEM of the 
percent of loaded 4SCa2+ that was released in 20 rain by individual 
oocytes in response to the stimulus. 
Oxidant Production.  The neutrophil suspension was maintained 
in PBS at 104 cells//A at room temperature until use. 10/zl of the 
neutrophil suspension were  placed in a single well of a 96-well mi- 
crotiter plate. Cells in all wells were stimulated simultaneously  by 
adding 90/zl of a cocktail containing 40/zl of HBSS, 50 #1 of Di- 
ogenes chemiluminescence  reagent (National Diagnostics Inc., At- 
lanta, GA) using a multichannel pipetter, prepared according to 
the instructions of the manufacturer, and the indicated agonists. 
The plate was immediately placed in a luminometer (Labsystems 
Luminoskan, Helsinki, Finland) at 37~  and the instantaneous lu- 
minescence produced by each sample was recorded every 30 s for 
6 min. The lag time for data collection after activation of the cells 
was between 15 and 20 s, allowing measurement of the peak but 
not the initial rate of superoxide production. 
Results 
Binding of fMLF to neutrophils results in rapid, transient 
increases in [Ca2+]i that can be monitored by calcium-sensi- 
tive dyes to follow receptor activation in real time (12). After 
the initial rise,  [Ca2+]i declines rapidly to a new sustained 
level that, at saturating concentrations of ligand, substan- 
tially exceeds the prestimulation baseline. When human neu- 
trophils were stimulated with the pentapeptides N-formyl- 
MNleLFF (fMNleLFF), N-acetyl-MNIeLFF (acMNIeLFF) 
or the unacylated counterpart H-MNleLFF, transient eleva- 
tions in  [Ca2+]i  were  observed  whose kinetics were indis- 
tinguishable from those elicited with fMLF (Fig.  1 A). The 
magnitude of both the peak and sustained levels of [Ca  2  +  ]i 
was dependent on the ligand concentration tested. Neutro- 
phil [Ca2+]~ also rapidly increased  upon stimulation with 
two other neutrophil chemoattractants, C5a and IL-8. How- 
ever, [Ca  2+ ]i then declined from the peak level more rapidly 
than was observed  with the pentapeptides and fMLF, and 
the sustained increase after stimulation with saturating con- 
centrations of ligand only slightly exceeded the prestimula- 
tion baseline. This suggested that the three pentapeptides in- 
teract with a receptor or class of receptors  similar to those 
for fMLF, but distinct from those for CSa and IL-8.  The 
EC50 for the unacylated pentapeptide was "o10 nM, a value 
that was lO-fold higher than that for fMLF. fMNleLFF and 
acMNIeLFF were equipotent but were '~10-fold more po- 
tent than fMLF (Fig.  1 B). 
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Figure 1.  Calcium mobilization in human neutrophils  stimulated  by 
synthetic  peptides  with different  NH2-terminal  modifications.  (A) Ki- 
netics. Ratio fluorescence was monitored from neutrophils  loaded with 
FUKA-2 before and during stimulation  with the substance indicated  at 
the top right of each box at the concentration indicated at the beginning 
To examine the ability  of the pentapeptides  to activate 
microbicidal functions of the human neutrophil, we mea- 
sured superoxide production by superoxide dismutase-inhib- 
itable chemiluminescence. Fig. 2 shows that the N-formyl-, 
N-acetyl-, and unacylated pentapeptides could all stimulate 
superoxide formation with the same kinetics as for fMLF. 
Superoxide production peaked at ~30 s after stimulation, and 
then rapidly decreased to low but sustained levels. In con- 
trast, the unacylated counterpart of fMLF, H-MLF, was in- 
active even at micromolar concentrations (Figs. 2 and 3). The 
rank order of potency for the Peptides tested was identical 
to that determined for calcium mobilization (Fig. 3). Again 
the unacylated pentapeptide had high activity, with an ECso 
10-fold higher than for fMLF. 
In the context of the structure-activity relationships pre- 
viously reported for N-formyl-tri and tetrapeptides, the high 
activity of acMNleLFF and H-MNleLFF was surprising. To 
show that the analogues activate neutrophils  via the same 
receptors as fMLF, we first performed sequential stimulation 
studies with the pentapeptides, fMLF, C5a, IL-8 and ATP, 
all of which are able to induce transient elevations of [Ca  2  +  ]i 
in human neutrophils.  After responding to an initial stimu- 
lation with saturating concentrations of fMLF or any of the 
three pentapeptides, neutrophils became completely insensi- 
tive to a second stimulation with 1 nM fMLF, the ECs0 for 
fMLF, given 200 s after the first stimulus (Fig. 4 A). In con- 
trast,  saturating concentrations of ATP, IL-8, or CSa could 
only weakly attenuate the calcium response to 1 nM f'MLF. 
The desensitization  patterns observed for fMLF, C5a,  and 
ATP confirm those previously reported by Didsbury et al. 
(16). The rank order of potency for desensitization  of the 
full response to I nM fMLF was fMNleLFF =  acMNleLFF 
> fMLF > H-MNIeLFF, identical to that determined for cal- 
cium mobilization  and superoxide production (Fig. 4 B). 
Moreover, any one pentapeptide given as a first stimulus could 
fully desensitize neutrophil responsiveness to any other pen- 
tapeptide given as a second stimulus (data not shown). Con- 
versely, saturating concentrations  (10-fold greater than the 
ECs0) of fMLF or any of the pentapeptides could only par- 
tially attenuate neutrophil responsiveness to a I nM dose of 
CSa, the ECs0 for CSa, whereas a saturating  concentration 
of CSa completely desensitized the cell to a second stimula- 
tion with 1 nM C5a (Fig. 5). Thus the desensitization prop- 
erties of all of the pentapeptides are concordant with those 
of fMLF and differ from those of the other neutrophil acti- 
vators tested. Taken together, these data suggest that the Pen- 
tapeptides specifically activate the same neutrophil receptor 
or class of receptors as fMLF. 
To further characterize the receptor specificity  of the penta- 
of each tracing. Test ligands were added at t  =  50 s. The tracings shown 
are from the same experiment which is representative of four experiments. 
(B) Concentration dependence. The amplitude of the peak change in fluores- 
cence is shown as a function of peptide concentration.  The data represent 
single determinations obtained at the indicated concentration for each peptide 
during the same experiment.  The key for each curve is indicated  at the 
top left.  The data  are representative  of two separate experiments. 
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Figure  2.  Activation  of the neutrophil respiratory burst 
by synthetic Peptides with different NHz-terminal modificat- 
ions: kinetics. Neutrophils were st/muhted with the substance 
indicated at the top of each panel in the presence (open circles) 
or absence (solid circles) of superoxide dismutase 1 #g/ml. 
Peptides were tested at 500 nM.  Superoxide production is 
quantified as relative luminescence units. 
peptides,  they were used to stimulate calcium release from 
frog oocytes expressing only a single type of human phago- 
cyte receptor,  either FPR,  or the highly related  receptors 
FPRL1R  and  the putative FPRL2  product,  after  micro- 
injection of specific cR.NA synthesized in vitro from the cor- 
responding cloned open reading frames (Fig.  6).  All three 
pentapeptides at  100 nM  could stimulate calcium release 
from oocytes expressing FPR, but not from those expressing 
FPRL1R or from oocytes injected with the FPRL2 cRNA. 
In contrast, and as previously reported (10), oocytes expressing 
either FPR or FPRL1R could be activated  by fMLF at 100 riM. 
The ECs0 for calcium release from oocytes expressing FPR 
was 10 nM for the unacylated pentapeptide, a value similar 
to that measured for calcium mobilization by this peptide 
in neutrophils. This value was 10-fold higher than that mea- 
sured in parallel experiments using fMLF (Fig.  7). 
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Figure  3.  Activation  of the neutrophil respiratory burst by synthetic 
peptides with different NH2-terminal modifications: concentration depen- 
dence, The peak luminescence  yield for the indicated concentration range 
is shown for each peptide. Data represent the means of values obtained 
in the following number of independent experiments: H-MNleLFF, 5; 
fMLF, 6; H-MLF, 2; and fMNleLFF, 5. 
Discussion 
The present work demonstrates that the nonformylated 
peptide H-MNleLFF  can activate  with high potency the 
human N-formylpeptide receptor.  When used to stimulate 
neutrophils, the peptide is a potent activator of the microbi- 
cidal respiratory burst, whereas H-MLF, the unacylated form 
of the potent prototype fMLF, is completdy inactive at con- 
centrations as high as 1 ~M. 
H-MNIeLFF did not activate the related human receptors 
FPRL1R or the FPRL2 product, which are 69 and 56% iden- 
tical in amino acid sequence to FPR, respectivdy. These results, 
based on expression of the cloned receptors in flog oocytes, 
together with the shared patterns of desensitization revealed 
by sequential stimulation experiments in human neutrophils, 
strongly suggest that  the neutrophil responses  elicited  by 
H-MNleLFF and the other pentapeptides are mediated by 
FPR. FPRLIR is a low affinity receptor for fMLF (Kd  = 
430 riM; ECs0 for calcium mobilization >  100 riM) (6, 10). 
fMLF does not bind to COS cells transfected with the FPRL2 
open reading frame, nor does fMLF activate oocytes injected 
with FPRL2 cRNA (8, 9). The negative results with FPRL2 
are reasonable,  as its sequence is more divergent than the 
FPRL1R sequence from that of FPR, yet they must be inter- 
preted with caution since physical expression of the FPRL2 
product on the plasma membrane of transfected COS cells 
and microinjected frog oocytes has not yet been demonstrated. 
The sensitivity of FPR to N-formylpeptides points to bac- 
teria and mitochondria as reasonable sources of its natural 
ligands. However, their importance as natural sources ofligands 
for I~PR has not yet been demonstrated in vivo. The ability 
of H-MNleLFF to activate FPR now implies that natural 
ligands for FPR may be produced by sources other than bac- 
teria and mitochondria. A data base search revealed several 
natural proteins that contain the internal sequence MLLFE 
Whether this specific peptide exists in vivo and its activity 
relative to H-MNleLFF remain to be determined. 
Previous studies of the structural requirements for binding 
ofligands to FPR have measured the ability of test compounds 
to displace labded N-formylpeptides from neutrophfls or from 
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Figure  4.  Receptor selectivity of MNleLFF analogs: desensitization of 
calcium transients  elicited by fMLF. (A) Kinetics. Ratio fluorescence was 
monitored from neutrophils  loaded with FURA-2 before and during se- 
quential  addition  of test  substances at the times indicated by the arrows. 
The concentrations  and identities  of each stimulus  are indicated  to the 
right of each arrow. The concentration of the first agonist is saturating 
in each case, whereas the concentration of the second stimulus, 1 nM fMLF, 
is the ECs0 for calcium mobilization. The tracings  shown are from the 
same experiment  which is representative  of three experiments.  (B) Con- 
centration  dependence. The amplitude of the peak change in fluorescence 
in response to 1 nM fMLF was plotted as a function of the concentration 
of the agonists indicated  in the box at the top right of the panel, in each 
case added 200 s before the addition of 1 nM fMLF. The data, presented 
as percent of the full non-desensitized  response to 1 nM fMLF, represent 
single determinations obtained at the indicated concentration for each peptide 
during the same experiment,  and are representative of two separate experi- 
ments.  Open symbols and dashed lines are for agonists capable of complete 
desensitization;  solid symbols and solid lines are for agonists capable of par- 
tial desensitization. 
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Figure  5.  Receptor selectivity 
of MNIeLFF analogs: desensitiza- 
tion of calcium transients elicited 
by C5a. The experimental design 
is as indicated in the legend to Fig. 
4. The concentrations  of the first 
agonist are 10-fold  greater than the 
corresponding  ECs0 in each case. 
The tracings shown are from the 
same experiment which is repre- 
sentative  of two experiments. 
Figure  6.  Delineation of the receptor for fMNleLFF, acMNIeLFF and 
H-MNleLFF. Xenopus  oocytes were injected with a solution  containing 
200 ng of Hb60 poly(A) + RNA (an RNA that lacks transcripts for FPR, 
FPRL1,  and FPILL2, but that contains  transcripts  for a complementary 
human factor required to link FPR and FPRLIR to signal transduction 
processes in the oocyte [10, 15]), and 10 ng of the cRNA indicated below 
each column. 3 d after injection, oocytes were treated with the indicated 
stimulus at 100 nM and calcium release was measured. The data are from 
a single experiment  representative  of two additional  experiments.  Each 
data point represents the mean _+ SEM from 4 to 6 oocytes. Basal amounts 
of calcium efflux and calcium uptake were similar for all experimental con- 
ditions. 
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Figure  7.  Rehtive  sensitivity  of FPR to fMLF  and H-MNhLFF.  Xeno/ms 
oocytes were injected with 200 ng of HL-60 poly(A)  + RNA and 10 ng 
of FPR cRNA. 3 d after injection, oocytes  were stimulated with either 
fMLF (solid circles) or H-MNIeLFF (open boxes) at the indicated concen- 
trations and calcium release was measured. Each data point represents the 
mean _+ SEM from 4-6 oocytes. The data are from a single experiment 
representative of two separate experiments. Basal amounts of calcium efflux 
and calcium uptake were similar for all experimental conditions. 
FPR expressed in  heterologous  cell types,  and  to activate 
cellular responses. Based on biochemical studies of human 
neutrophils using real-time quenching of fluorescein-labeled 
N-formylpeptides of different length, Sklar (17) has proposed 
that  the  ligand-binding  site  of FPR  can  accommodate  a 
tetrapeptide,  and is composed of hydrophobic and proton- 
donating subdomains on the extraceUular face of the receptor. 
The hydrophobic subdomain may involve several of the seven 
membrane-spanning hydrophobic domains of the receptor in- 
ferred from the deduced amino acid sequence; Hisg0 in the 
proposed first extracellular loop could be a proton donor. In 
this model, the formyl group resides at limited depth in the 
interhelical channel,  and the COOH terminus  of the pep- 
tide contacts determinants  in the extraceUular loops. Anal- 
ysis of chimeric FPR:FPRL1R receptors has suggested that 
differences in all three of the extraceUular loops and possibly 
the NH2-terminal segments account for the large difference 
in affinity for fMLF observed for FPR and FPRL1R (10, 18). 
The importance  of the transmembrane  domains for fMLF 
binding and signaling has not yet been addressed by muta- 
genesis  studies. 
The  decreased  potency  of  H-MNleLFF  relative  to 
fMNleLFF  supports  the importance  of N-formylation  for 
stabilizing the binding interaction,  whereas the small dimi- 
nution of potency of H-MNleLFF relative to fMLF suggests 
that differences in the COOH-terminal  sequence can com- 
pensate for the loss of the formyl group. However, N-acetyl- 
MLF exhibits the same loss of activity as does the unacylated 
tripeptide (2), whereas there is very little diminution of activity 
of N-acetyl-MNleLFF compared with its formylated analogue. 
This suggests that the added COOH-terminal sequence causes 
changes in the nature  of the binding  of the NH2-terminal 
amino  acid(s) compared with  that  of the tripeptide. 
Despite 20 yr of study, the biological role and importance 
of FPR have not been established, in part because of uncer- 
tainties regarding the identity of its natural ligands. The present 
findings increase this uncertainty,  in that N-formylation is 
no longer a conceptual constraint for a peptide to have high 
activity for FPR. The demonstration that N-formylation is 
not necessary for a peptide to potently activate FPR permits 
the existence of a nonformylated endogenous ligand in eu- 
karyotic organisms  to be more confidently considered. 
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